Understanding how abnormal Gas activation affects blood cancer
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms
This study is looking into the genetic changes that cause blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to help find new treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11056848 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind myeloid neoplasms, particularly focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). By utilizing advanced techniques like CRISPR gene editing and RNA sequencing, the study aims to identify specific genetic mutations that lead to abnormal cell behavior. The goal is to uncover potential therapeutic targets that could lead to effective treatments for patients suffering from these aggressive blood cancers. Patients may benefit from insights into new treatment strategies based on the genetic underpinnings of their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia or myelodysplastic syndromes, particularly those with specific genetic mutations.
Not a fit: Patients with other types of leukemia or those without the identified genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.
How similar studies have performed: Previous research has shown promise in targeting genetic mutations in blood cancers, indicating that this approach could yield significant advancements.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Papapetrou, Eirini — Icahn School of Medicine at Mount Sinai
- Study coordinator: Papapetrou, Eirini
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.